Answers are grounded in this paper and cite their sources.
Background and aims In this study of metabolic dysfunction–associated steatohepatitis (MASH)–related Child-Pugh A cirrhosis (MASH cirrhosis), we used the cholate challenge test to quantify baseline disease severity and the subsequent impact of resmetirom treatment. Methods Thirty-two subjects enrolled in the Phase 3 open-label MAESTRO-NAFLD-1 trial with MASH cirrhosis underwent baseline dual cholate shunt testing, and 25 had subsequent retesting at 28 and 48 weeks. Blood was sampled from 0 to 90 minutes, serum concentrations measured, and parameters of function (disease severity index [DSI]), portal-systemic shunting (SHUNT%), and clinical risk (RISK ACE) were calculated. Responders were defined by > 2-point decrease in DSI, stable subjects by a ΔDSI within ±2, and nonresponders by > 2-point increase. Results Baseline DSI (22 ± 7) and SHUNT% (36% ± 16%) were consistent with significant functional impairment and portal-systemic shunting. Responder rates were 14% by 28 weeks and 38% by 48 weeks ( P = .0254). After 28 weeks, 87% of subjects were either stable or showed improvement. After 48 weeks, 83% of subjects were either stable or showed improvement, with a significant reduction in mean RISK ACE from baseline (−4.0%, P = .041). Subjects with the greatest hepatic impairment (n = 12, baseline DSI >23) showed the greatest reduction in RISK ACE (−7.5%, P = .053). Conclusion MASH cirrhosis is characterized by a broad spectrum of hepatic impairment and portal-systemic shunting. DSI, SHUNT%, and RISK ACE may provide early estimates of potential clinical benefit with resmetirom treatment. MAESTRO-NAFLD-1 was registered at ClinicalTrials.gov (NCT04197479).
No takes yet. Share an insight, caveat, or question.
Alkhouri et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: